Targeting changes in mitochondria to overcome drug resistance in acute myeloid leukemia
Official title: Targeting mitochondrial dynamics in drug-resistant acute myeloid leukemia
Funded at Rutgers Biomedical and Health Sciences · NIH-11035199 · Data updated 2026-11-12
This study is looking at how changes in tiny parts of your cells called mitochondria might make it harder for some people with acute myeloid leukemia to respond to a common treatment, and it hopes to find new ways to improve those treatments for patients who are struggling.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | March 3, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $249,000 |
| NIH project number | 5R00CA252602-05 |
| Project ID | NIH-11035199 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with acute myeloid leukemia who have developed resistance to venetoclax.
✕Less likely to help
Patients with acute myeloid leukemia who have not been treated with venetoclax or those with other types of leukemia may not benefit from this research.
What this research studies
This research investigates how changes in mitochondrial structure and function contribute to drug resistance in acute myeloid leukemia (AML). It focuses on the role of specific genes that affect mitochondrial dynamics, particularly in patients who have developed resistance to the drug venetoclax. By using advanced techniques like CRISPR, the study aims to identify potential new treatment strategies that could enhance the effectiveness of existing therapies. Patients may benefit from a deeper understanding of their disease and potentially new therapeutic options that target these mitochondrial changes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with drug-resistant acute myeloid leukemia.
How similar studies have gone: Other research has shown promising results in targeting mitochondrial dynamics in cancer treatment, suggesting that this approach may be effective.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Glytsou, Christina — Rutgers Biomedical and Health Sciences
- Study coordinator: Glytsou, Christina
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.